Current Price and Development
The current price of Bayer stock on May 24, 2025, was approximately 24.45 EUR, representing a slight decrease of 0.02 EUR or 0.08% compared to the previous day. Interestingly, the stock surpassed the 200-day moving average on May 20, 2025, indicating a long-term positive trend reversal. This development is particularly noteworthy as it occurs amid a weaker market environment.
Market Development and Forecasts
Analysts continue to expect positive development for Bayer stock. The average price target is around 25.14 EUR, with some even seeing potential for a price target of about 26.50 EUR. Bank of America has raised its rating for Bayer stock from “Neutral” to “Buy,” highlighting the positive outlook for the stock.
Company Development
Financial results indicate that Bayer has confirmed its goals for 2025, despite a decline in adjusted consolidated earnings per share of 11.7% to 2.49 EUR. This decline was primarily driven by reduced EBITDA before special items in the Crop Science division. Bayer continues to face challenges, particularly from the acquisition of Monsanto and the associated legal disputes over glyphosate.
Importance for Retail Investors
As part of the DAX, Bayer stock is particularly interesting for retail investors. It offers the opportunity to diversify portfolios and benefit from the stability of a large corporation.
In summary, Bayer stock shows a positive development supported by the surpassing of the 200-day line and positive analyst forecasts. Despite challenges, Bayer remains a central player in the DAX and offers interesting opportunities for investors.